Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Average Rating of “Moderate Buy” from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $28.50.

Several equities analysts have recently weighed in on the company. Wells Fargo & Company reduced their price target on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. JPMorgan Chase & Co. lowered their price objective on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Weiss Ratings downgraded Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, August 11th. Wedbush cut their price target on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, August 3rd. Finally, Zacks Research upgraded shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th.

Monte Rosa Therapeutics Price Performance

Monte Rosa Therapeutics stock opened at $14.30 on Monday. The company’s 50 day moving average price is $20.13 and its two-hundred day moving average price is $18.82. Monte Rosa Therapeutics has a 52 week low of $4.51 and a 52 week high of $25.77. The stock has a market cap of $1.22 billion, a P/E ratio of -8.12 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. The company had revenue of $8.97 million during the quarter, compared to analysts’ expectations of $12.91 million. On average, equities analysts anticipate that Monte Rosa Therapeutics will post -1.32 EPS for the current year.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, insider Sharon Townson sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the completion of the transaction, the insider owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Anthony M. Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at $231,100. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 81,778 shares of company stock valued at $1,768,581 in the last three months. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GLUE. California State Teachers Retirement System raised its holdings in Monte Rosa Therapeutics by 39,776.6% in the 2nd quarter. California State Teachers Retirement System now owns 1,311,543 shares of the company’s stock worth $31,739,000 after acquiring an additional 1,308,254 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Monte Rosa Therapeutics by 239.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 65,451 shares of the company’s stock worth $1,584,000 after buying an additional 46,172 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Monte Rosa Therapeutics by 61.1% during the 2nd quarter. Wellington Management Group LLP now owns 207,427 shares of the company’s stock worth $5,020,000 after acquiring an additional 78,635 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Monte Rosa Therapeutics in the second quarter worth about $15,778,231,000. Finally, Empowered Funds LLC purchased a new stake in Monte Rosa Therapeutics in the 2nd quarter worth approximately $7,968,000. 79.96% of the stock is owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.